Diabetes - Publications - Faculty & Research - Harvard Business School

Filter Results: (23)

Filter Results: (23)

Show Results For

Page 1 of 23 Results →

Are you looking for?

→Search All HBS Web

August 2024 (Revised February 2025)
Case

Novo Nordisk Foundation

By: Debora L. Spar and Julia M. Comeau

In 2024, Novo Nordisk A/S was one of the most profitable firms in the world, thanks largely to just two GLP-1-based drugs, Ozempic and Wegovy. Unusually, this incredibly profitable firm was controlled not by individual private shareholders, but by a non-profit... View Details

Keywords: Pharmaceutical Companies; Diabetes; Obesity; Foundation; Non-profit Management; Profit; Corporate Governance; Business or Company Management; Corporate Social Responsibility and Impact; Expansion; Philanthropy and Charitable Giving; Nonprofit Organizations; Pharmaceutical Industry; Denmark; Europe

April 2024 (Revised July 2024)
Case

Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs

By: Joseph L. Badaracco, Tom Quinn and John Schultz

Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details

October 2023
Case

Vida Health: Transforming Chronic Disease Treatment

By: William Sahlman and Nicole Tempest Keller

San Francisco based Vida Health, founded by Stephanie Tilenius, former vice president of Commerce and Payments at Google, was a B2B digital health startup focused on the treatment of cardiometabolic conditions, such as diabetes and obesity. Its innovative digital... View Details

Keywords: Corporate Strategy; Growth and Development Strategy; Demand and Consumers; Health Care and Treatment; Product Marketing; Risk and Uncertainty; Technological Innovation; Health Industry; Technology Industry; United States; California; San Francisco

July 2023
Case

DayTwo: Going to Market with Gut Microbiome (Abridged)

By: Ayelet Israeli

DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals. After a first year of trial rollout in... View Details

Keywords: Business Startups; AI and Machine Learning; Nutrition; Market Entry and Exit; Product Marketing; Distribution Channels

March 2023 (Revised March 2025)
Case

Close Concerns: Diabetes Research and Advocacy

By: Regina Herzlinger and Brian L. Walker

Diagnosed with diabetes at the age of 18, Kelly Close understood the importance of balancing consistency and iteration. This principle had also informed her professional work, which started with a rapid promotion from financial analyst at Goldman Sachs to an analyst... View Details

Keywords: Diabetes; Health; Health Care; Health Care And Treatment; Health Care Outcomes; Health Care Industry; Knowledge Dissemination; Outcome or Result; Equality and Inequality; Business Model; Entrepreneurship

January 2023
Case

Vertex and the Cure for Type 1 Diabetes

By: Amitabh Chandra, William J Anderson and Silvia Mare

Keywords: Biotechnology Industry

January 2021
Case

Value-Based Insurance Design at Onex

By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal

The operating executives of Health and Benefits for Onex Partners, Megan Jackson Frye and Sam Camens, faced a challenge: Healthcare costs for employees of Onex’s portfolio companies were continuing to rise above the consumer price index, reflecting broader trends... View Details

November 2020
Teaching Note

DayTwo: Going to Market with Gut Microbiome

By: Ayelet Israeli

Teaching Note for HBS Case No. 519-010. DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals.... View Details

August 2020
Article

Do Physician Incentives Increase Patient Medication Adherence?

By: Edward Kong, John Beshears, David Laibson, Brigitte Madrian, Kevin Volpp, George Loewenstein, Jonathan Kolstad and James J. Choi

We conducted a randomized experiment (911 primary care practices and 8,935 nonadherent patients) to test the effect of paying physicians for increasing patient medication adherence in three drug classes: diabetes medication, antihypertensives, and statins. We measured... View Details

Keywords: Health Economics; Medication Adherence; Physician Payment Incentives; Primary Care; Quality Improvement; Health Care and Treatment; Motivation and Incentives; Behavior

Article

Navy Medicine Introduces Value-Based Health Care

By: Alee Hernandez, Robert S. Kaplan, Mary L. Witkowski, C. Forrest Faison III and Michael E. Porter

In 2016 the newly appointed surgeon general of the Navy launched a value-based health care pilot project at Naval Hospital Jacksonville to explore whether multidisciplinary care teams (known as integrated practice units, or IPUs) and measurement of outcomes could... View Details

Keywords: Military Health System; Health Care and Treatment; Cost Management; Projects

Find at Harvard

Register to Read

March 2019
Case

DayTwo: Going to Market with Gut Microbiome

By: Ayelet Israeli and David Lane

DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals. After a first year of trial rollout in... View Details

January 2018 (Revised June 2018)
Case

Medtronic: Navigating a Shifting Healthcare Landscape

By: Robert S. Kaplan, Michael E. Porter, Thomas W. Feeley and Alee Hernandez

Medtronic is adapting its strategy to changes in healthcare competition and payments. It has decided to develop new relationships with payers, hospitals, and physicians to become more accountable for patient outcomes and total costs. The case describes new forms of... View Details

Keywords: Value Based Health Care; Bundled Payments; Health Care and Treatment; Cost Management; Value Creation; Supply Chain Management; Customer Value and Value Chain; Health Industry; Medical Devices and Supplies Industry; United States; Netherlands

August 2017 (Revised July 2018)
Case

MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work

By: Elie Ofek and Amanda Dai

In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to... View Details

Keywords: Health Care and Treatment; Product Launch; Product Positioning; Marketing Strategy; Adoption; Pharmaceutical Industry

April 2014 (Revised January 2015)
Background Note

Note on Mobile Healthcare

By: John A. Quelch and Margaret L. Rodriguez

Delivering health care to the global population was a challenge. Health care costs accounted for ten percent of world GDP by 2013. In the U.S., health care costs were expected to top $3.1 trillion in 2014. New technologies, shortages of trained personnel and... View Details

November 2012
Supplement

Amylin Pharmaceuticals (B)

By: Richard G. Hamermesh and Carin-Isabel Knoop

Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical... View Details

Keywords: Pharmaceuticals; Bristol-Myers Squibb; Health Care and Treatment; Pharmaceutical Industry; United States

January 2010
Teaching Note

The Joslin Diabetes Center (TN)

By: Michael E. Porter, Elizabeth O. Teisberg and Scott Wallace

Teaching Note for [710424]. View Details

Keywords: Health Care and Treatment; Groups and Teams; Medical Specialties; Programs; Opportunities; Service Delivery; Alliances; Value Creation; Health Industry; Boston

October 2009 (Revised January 2010)
Case

The Joslin Diabetes Center

By: Michael E. Porter, Elizabeth Olmsted Teisberg and Scott Wallace

The Joslin Diabetes Center in Boston, Massachusetts is a leading center for diabetes care, clinician training, and research. The incidence of diabetes is rising precipitously worldwide, challenging quality of life with its complications and rapidly accelerating health... View Details

Keywords: Integration; Service Delivery; Medical Specialties; Health Care and Treatment; Outcome or Result; Corporate Finance; Health Industry; Boston

April 2009
Teaching Note

Amylin Pharmaceuticals: Diabetes and Beyond (TN)

By: Richard G. Hamermesh and Rachel Gordon

Teaching Note for [809011]. View Details

Keywords: Negotiation Deal; Product Development; Success; Commercialization; Governing Rules, Regulations, and Reforms; Resource Allocation; Pharmaceutical Industry

December 2008 (Revised October 2013)
Case

Amylin Pharmaceuticals: Diabetes and Beyond (A)

By: Richard G. Hamermesh and Rachel Gordon

Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details

Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States

February 1999
Teaching Note

Wegmans Food Markets: Diabetes Counseling TN

By: David E. Bell

Teaching Note for (9-599-057). View Details

Keywords: Pharmaceutical Industry; Food and Beverage Industry

1
2
→